Biohaven Pharmaceutical

$86.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.40 (+1.65%) Today
$0.00 (0.00%) As of 12:59 AM UTC after-hours

Why Robinhood?

You can buy or sell BHVN and other stocks, options, and ETFs commission-free!

About BHVN

Biohaven Pharmaceutical Holding Company Ltd., also called Biohaven Pharmaceutical, is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. The listed name for BHVN is Biohaven Pharmaceutical Holding Company Ltd.

CEO
Vlad Coric
Employees
647
Headquarters
New Haven, Connecticut
Founded
2013
Market Cap
5.22B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
545.86K
High Today
$88.08
Low Today
$83.42
Open Price
$83.42
Volume
432.87K
52 Week High
$100.77
52 Week Low
$26.56

BHVN News

Benzinga19h

Recap: Biohaven Pharmaceutical Q4 Earnings

Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share

BHVN Earnings

-$2.97
-$1.98
-$0.99
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$2.97 per share
Actual
-$2.69 per share
Replay Earnings Call

You May Also Like

MU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure